Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer Kentaro SudoTaketo YamaguchiOsamu Yokosuka Original Article 30 March 2010 Pages: 249 - 254
Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3′,4′,5′,5,7-pentamethoxyflavone and tricin (4′,5,7-trihydroxy-3′,5′-dimethoxyflavone) Hong CaiStewart SaleAndreas J. Gescher Original Article 04 April 2010 Pages: 255 - 263
In vitro anti-mesothelioma activity of cisplatin–gemcitabine combinations: evidence for sequence-dependent effects Ilaria ZanellatoCarla Doriana BoidiDomenico Osella Original Article 06 April 2010 Pages: 265 - 273
Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy Ana Catarina PintoSusana ÂngeloSérgio Simões Original Article 09 April 2010 Pages: 275 - 284
Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake Valentina K. TodorovaYihong KaufmannV. Suzanne Klimberg Original Article 11 April 2010 Pages: 285 - 291
A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer Sunjoo AhnDong Jin HwangJames T. Dalton Original Article 11 April 2010 Pages: 293 - 304
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors Anne M. TraynorMaureen HewittGeorge Wilding Original Article 13 April 2010 Pages: 305 - 314
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma Fumihiko KanaiHaruhiko YoshidaMasao Omata Original Article 14 April 2010 Pages: 315 - 324
Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer Katsuhiro MasagoShiro FujitaMichiaki Mishima Original Article 17 April 2010 Pages: 325 - 330
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer Hiroyuki YamaguchiHiroshi SodaShigeru Kohno Original Article 17 April 2010 Pages: 331 - 338
Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability Francis LéviAbdoulaye KarabouéMohamed Bouchahda Original Article 17 April 2010 Pages: 339 - 348
Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice Cathrine L. DentonDaniel L. Gustafson Original Article 21 April 2010 Pages: 349 - 360
Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial Ourania KatopodisAris PolyzosVassilis Georgoulias Original Article 29 April 2010 Pages: 361 - 368
Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells Valentina ColomboMonica LupiPaolo Ubezio Original Article 30 April 2010 Pages: 369 - 379
Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N F. H. HausheerA. R. ParkerH. Kochat Original Article 04 May 2010 Pages: 381 - 391
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients Jill KolesarRichard C. BrundageGeorge Wilding Original Article 04 May 2010 Pages: 393 - 400
Combination effects of platinum drugs and N 1, N 11 diethylnorspermine on spermidine/spermine N 1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants Ramakumar TummalaPaula DiegelmanLakshmi Pendyala Original Article Open access 05 May 2010 Pages: 401 - 414
Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers Hiroko SugimotoTakuya IwamotoMasahiro Okuda Original Article 05 May 2010 Pages: 415 - 419
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice Jan H. BeumerJulie L. EisemanMerrill J. Egorin Original Article 05 May 2010 Pages: 421 - 430
A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone Lee P. RestaRoberto PiliChristopher J. Sweeney Original Article Open access 06 May 2010 Pages: 431 - 438
Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells Cao YangEdwin ChoyZhenfeng Duan Original Article 12 May 2010 Pages: 439 - 446
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose Kyle D. HolenChandra P. BelaniPeter T. C. Ho Original Article 12 May 2010 Pages: 447 - 454
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors Carlos CastanedaKellen L. MeadowsHerbert I. Hurwitz Clinical Trial Report 24 October 2010 Pages: 455 - 463
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE) Karen E. BullockWilliam P. PetrosJohanna C. Bendell Clinical Trial Report 16 November 2010 Pages: 465 - 474
Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer Xin-Hua XuJin SuMing-Qian Lu Short Communication 16 September 2010 Pages: 475 - 479
The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines Ravi P. SahuSanjay BatraSanjay K. Srivastava Short Communication 17 September 2010 Pages: 481 - 487
